MoneyWorks4Me

AstraZeneca Pharma India informs about redressal of investor complaints

16 Jan 2018 Evaluate

As required under Regulation 13 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the Report on Redressal of Investor Complaints for the quarter ended December 31, 2017.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..